Tecass26 Oct 2018 14:20
Ouch ...... just what you want on a Friday........ not
Ultragenyx Pharmaceutical Inc. [s:RARE] shares were halted in Friday premarket trade on news that its therapy UX007 failed to meet the primary endpoint in a phase 3 clinical trial. UX007 was being tested in patients with a rare disease called glucose transporter type-1 deficiency syndrome, but did not show a statistically significant reduction in the number of disabling movement disorders relative to the placebo, the phase 3 trial's primary endpoint, the company said. The trial, which enrolled 44 children and adults with the disease, also did not meet key secondary endpoints.